University of Wisconsin Carbone Cancer Center Becomes First in the World to Treat Patients with MRIdian’s Soft-Tissue-Tracking-Beam Control

September 10, 2014 9:14 AM ET

ViewRay’s MRIdian System Directly Tracks Tumor Motion Continuously During Treatment

September 10, 2014

CLEVELAND, Ohio, September 10, 2014—The MRIdian™ \ma-ˈri-dē-әn\ system from ViewRay™, a privately held medical device company, is now being used to treat patients at the University of Wisconsin Carbone Cancer Center in Madison, Wisconsin, the second clinical group in the world to treat patients with MRI-guided radiation therapy. With the treatment, the center also became the first clinic in the world to employ the soft-tissue tracking beam control feature of ViewRay’s MRIdian system.

The MRIdian system is the world’s first and only MRI-guided radiation therapy system. It uniquely provides continuous imaging during treatment so clinicians are able to see where the radiation dose is being delivered and adapt to changes and movement in the patient’s anatomy in real-time. The system tracks soft-tissues of the tumor directly, in fast planar images, then automatically compares the target to the plan and only allows treatment when the target is in range.

“We had a patient with very limited treatment options,” said Michael Bassetti, M.D., Ph.D., a radiation oncologist at the University of Wisconsin Carbone Cancer Center. “We used MRI-guided radiation therapy employing the soft-tissue tracking beam control feature because of the size and location of this patient’s tumor combined with the large observable motion.”

John Bayouth, Ph.D., Chief of Physics at the University of Wisconsin Carbone Cancer Center, said, “Minimizing the radiation dose to the normal tissues while verifying the dose delivered to the tumor during treatment delivery is one of the overriding goals of radiotherapy. We want to be able to see changes and respond accordingly.”

Paul Harari, M.D., Professor and Chairman of the Department of Human Oncology at the University of Wisconsin School of Medicine and Public Health, said, “Incorporating continual MR image-guidance and treatment control is new to radiation therapy and offers the potential to change the way clinicians treat cancer patients.”

About ViewRay

ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The MRIdian system provides continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient’s anatomy. For more information, visit http://www.viewray.com.

About the Carbone Cancer Center

An integral part of the UW School of Medicine and Public Health, the Carbone Cancer Center unites more than 280 physicians and scientists who work together in translating discoveries from research laboratories into new treatments that benefit cancer patients. Its mission is primarily achieved through research programs that bring scientists together from many different disciplines. More than 30,000 people are seen annually for diagnosis, therapy, follow-up care or consultations at UW Hospital and Clinics, as well as our other clinical locations. UW Hospital and Clinics is consistently in the top 25 of 50 hospitals providing the best cancer care and research efforts in U.S. News and World Report's "America's Best Hospitals", which is published annually. Most recently, UWHC was named the number one hospital in Wisconsin in this report.

ViewRay and MRIdian are trademarks of ViewRay Incorporated.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier
Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

**Contact:**
Michael Saracen  
Senior Director, Marketing  
ViewRay Incorporated  
Phone: +1 440.703.3210, ext. 200  
Email: media@viewray.com